<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48493">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776528</url>
  </required_header>
  <id_info>
    <org_study_id>12-0101</org_study_id>
    <nct_id>NCT01776528</nct_id>
  </id_info>
  <brief_title>Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of NGM282, both single
      dose and multiple doses, in normal healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>7 days and 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>7 days and 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>7 days and 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the pharmacodynamics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 1 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 2 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 3 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 4 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 5 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 6 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 1 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 2 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 3 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 4 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 5 vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM282 Dose 6 vs Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM282</intervention_name>
    <arm_group_label>Cohort 1 SAD</arm_group_label>
    <arm_group_label>Cohort 2 SAD</arm_group_label>
    <arm_group_label>Cohort 3 SAD</arm_group_label>
    <arm_group_label>Cohort 4 SAD</arm_group_label>
    <arm_group_label>Cohort 5 SAD</arm_group_label>
    <arm_group_label>Cohort 6 SAD</arm_group_label>
    <arm_group_label>Cohort 7 MAD</arm_group_label>
    <arm_group_label>Cohort 8 MAD</arm_group_label>
    <arm_group_label>Cohort 9 MAD</arm_group_label>
    <arm_group_label>Cohort 10 MAD</arm_group_label>
    <arm_group_label>Cohort 11 MAD</arm_group_label>
    <arm_group_label>Cohort 12 MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1 SAD</arm_group_label>
    <arm_group_label>Cohort 2 SAD</arm_group_label>
    <arm_group_label>Cohort 3 SAD</arm_group_label>
    <arm_group_label>Cohort 4 SAD</arm_group_label>
    <arm_group_label>Cohort 5 SAD</arm_group_label>
    <arm_group_label>Cohort 6 SAD</arm_group_label>
    <arm_group_label>Cohort 7 MAD</arm_group_label>
    <arm_group_label>Cohort 8 MAD</arm_group_label>
    <arm_group_label>Cohort 9 MAD</arm_group_label>
    <arm_group_label>Cohort 10 MAD</arm_group_label>
    <arm_group_label>Cohort 11 MAD</arm_group_label>
    <arm_group_label>Cohort 12 MAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, between 18 and 65 years of age, inclusive

          -  BMI range is 20-35 kg/m2, inclusive for the SAD Module, and 25-35 kg/m2, inclusive
             for the MAD Module at Screening;

          -  In good health, determined by no clinically significant findings from medical
             history, physical exam, 12 lead ECG, clinical laboratory findings, and vital signs at
             Screening and Day -1

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,
             neurological, or psychiatric disorder (as determined by the PI)

          -  History of significant hypersensitivity, intolerance, or allergy to any drug
             compound, food, or other substance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex M DePaoli, MD</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://ngmbio.com/</url>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 30, 2013</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
